Our businesses have rebounded nicely from the COVID lows with silicone hydrogel lenses and myopia management leading CooperVision and fertility and PARAGARD driving CooperSurgical.
For the quarter and reporting all percentages on a constant-currency basis, consolidated revenues were $720 million, with CooperVision at $523 million, up 25%; and CooperSurgical at $197 million, up 58%.